Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis

被引:0
|
作者
Vega, Luis [1 ]
Simian, Daniela [1 ]
Gajardo, Abraham I. [2 ]
Salinas, Marcelo [1 ]
Urra, Andrea [1 ]
Cattaneo, Maximo [1 ]
Pino, Rosario [1 ]
Roblero, Juan P. [1 ]
Urzua, Alvaro [1 ]
Rojas, Katherine [1 ]
Poniachik, Jaime [1 ]
机构
[1] Hosp Clin Univ Chile, Med Dept, Gastroenterol Sect, Santiago, Chile
[2] Hosp Clin Univ Chile, Med Dept, Crit Patient Care Unit, Santiago, Chile
关键词
Metabolic dysfunction-associated fatty liver disease; Liver fibrosis; Coronary heart disease;
D O I
10.1016/j.aohep.2024.101511
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction and Objectives: Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at an increased cardiovascular risk. On the contrary, non-alcoholic fatty liver disease (NAFLD) is highly prevalent in patients with coronary heart disease (CHD). However, it is not known whether patients with significant CHD show a higher frequency of liver fibrosis. This study aimed to determine the frequency of MASLD and liver fibrosis in patients with CHD and to assess whether coronary stenosis is significantly associated with MASLD and fibrosis. Patients and Methods: This observational and analytical study included adult patients without any known liver disease who underwent coronary angiography for suspected coronary artery disease (Jul 2021-Jul 2022). The presence of significant CHD (> 50% stenosis of at least one coronary artery) was determined. Liver elastography (FibroScan (R)) was performed up to 6 months after the coronary angiographic study to determine liver fibrosis, a measurement of liver stiffness (> 6.5 Kpa). Fisher's test, Mann-Whitney U test, and logistic regression models were used (p < 0.05). Results: The study included 113 patients (76% men, average age: 63 years [standard deviation: 9.9]), of which 72% presented with significant CHD. The prevalence rate of MASLD was 52%. Liver fibrosis was present in 12% of the patients and all patients in the significant CHD group (p = 0.007). An increase in the number of vessels with significant CHD increased the probability of liver fibrosis (odds ratio, 1.79; 95% confidence interval, 1.06-3.04; p = 0.029). Conclusions: MASLD is highly prevalent in patients with significant CHD but without known liver damage. These data suggest that MASLD and liver fibrosis should be investigated in patients with CHD. The presence of confounding variables, especially the presence of type 2 diabetes mellitus, should be evaluated in further studies. (c) 2024 Published by Elsevier Espa & ntilde;a, S.L.U. on behalf of Fundaci & oacute;n Cl & iacute;nica M & eacute;dica Sur, A.C. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
    Platek, Anna E.
    Szymanska, Anna
    [J]. CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 187 - 192
  • [2] Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
    Lee, Hyeok-Hee
    Lee, Han Ah
    Kim, Eun-Jin
    Kim, Hwi Young
    Kim, Hyeon Chang
    Ahn, Sang Hoon
    Lee, Hokyou
    Kim, Seung Up
    [J]. GUT, 2024, 73 (03) : 533 - 540
  • [3] Liver Cell Mitophagy in Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Fibrosis
    Chen, Jiaxin
    Jian, Linge
    Guo, Yangkun
    Tang, Chengwei
    Huang, Zhiyin
    Gao, Jinhang
    [J]. ANTIOXIDANTS, 2024, 13 (06)
  • [4] Metabolic dysfunction-associated steatotic liver disease and the heart
    Driessen, Stan
    Francque, Sven M.
    Anker, Stefan D.
    Cabezas, Manuel Castro
    Grobbee, Diederick E.
    Tushuizen, Maarten E.
    Holleboom, Adriaan G.
    [J]. HEPATOLOGY, 2023,
  • [5] Menopause and metabolic dysfunction-associated steatotic liver disease
    Polyzos, Stergios A.
    Goulis, Dimitrios G.
    [J]. MATURITAS, 2024, 186
  • [6] Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
    Castillo-Nunez, Yulino
    Almeda-Valdes, Paloma
    Gonzalez-Galvez, Guillermo
    Arechavaleta-Granell, Maria del Rosario
    [J]. CURRENT DIABETES REPORTS, 2024, 24 (07) : 158 - 166
  • [8] Clinical and genetic risk factors for progressive fibrosis in metabolic dysfunction-associated steatotic liver disease
    Kaplan, David E.
    Teerlink, Craig C.
    Schwantes-An, Tae-Hwi
    Norden-Krichmar, Trina M.
    DuVall, Scott L.
    Morgan, Timothy R.
    Tsao, Philip S.
    Voight, Benjamin F.
    Lynch, Julie A.
    Vujkovic, Marijana
    Chang, Kyong-Mi
    [J]. HEPATOLOGY COMMUNICATIONS, 2024, 8 (07)
  • [9] Nutrients associated with metabolic dysfunction-associated steatotic liver disease
    Jeong, Seogsong
    [J]. JOURNAL OF HEPATOLOGY, 2024, 80 (02) : e81 - e82
  • [10] Visceral Fat and Diabetes: Associations With Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Kumar, Ashish
    Arora, Anil
    Sharma, Praveen
    Jan, Shayesta
    Ara, Ishrat
    [J]. JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2025, 15 (01)